> Cinclus Pharma secured funding to support its preparations for a phase 2 trial of a potassium competitive acid blocker in erosive gastroesophageal reflux disease. Statement
> Mereo BioPharma completed its reverse merger with OncoMed Pharmaceuticals and began trading on Nasdaq. The developments extend Mereo’s cash runway out to the middle of next year. Release I More
> The FDA granted orphan drug status to Autolus Therapeutics’ CD19-CD22 cell therapy AUTO3 in the treatment of acute lymphoblastic leukemia. Statement
> Marinomed Biotech posted top-line data from a phase 3 clinical trial of allergic rhinitis nasal spray Budesolv. The trial found Budesolv had comparable effects to another budesonide product but at a lower dose. Release
> Cytura Therapeutics raised seed funding to develop drugs targeting genomic instability in cancer. A syndicate led by Thuja Capital Healthcare put up the money. Statement
> Oxurion completed enrollment in a phase 1 trial of plasma kallikrein inhibitor THR-149 ahead of schedule. The milestone positions Oxurion to share initial data on the diabetic macular edema prospect early in the third quarter. Release